Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
511 Diphenoxylate HCl 2.5mg with Atropine Sulphate 0.025mg Tablet A07DA01-922-T10-01-XXX B Symptomatic treatment of acute and chronic diarrhoea None ADULT: 2 tablets 4 times daily, later reduced when diarrhoea is controlled.
Maintenance: 2 tablets once daily as needed (Max: 8 tablets daily)
512 Diphtheria and Tetanus Vaccine Injection J07AM51963P3001XX C+ Immunisation against diphtheria and tetanus. 0.5ml by deep SC or IM injection. Dosing is according to Immunisation Schedule under NIP.
513 Diphtheria Antitoxin Injection J07AF01000P3001XX B Diphtheria Therapeutic: 10,000 - 30,000 units by IM or IV. Increase to 40,000 - 100,000 units in severe cases. Doses up to 30,000 units may be given IM
514 Diphtheria, Pertussis, Tetanus Vaccine Injection J07AJ52963P3001XX C+ Immunisation against diphtheria, pertussis and tetanus. 0.5ml by IM. Dosing is according to Immunisation Schedule under NIP.
515 Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content) Suspension for injection (Tdap) J07AJ52-963-P30-01-XXX C+ Indicated for passive protection against pertussis in early infancy following maternal immunisation during pregnancy. None A single 0.5 ml dose of the vaccine is recommended for pregnant women during the second or the third trimester of pregnancy.
For deep intramuscular injection, preferably in the deltoid region
516 Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Virus, Haemophilus Influenza Type B (DTaP-IPV-HiB) Vaccine Injection J07CA06963P3001XX C+ Immunisation of children against Diphtheria, Tetanus, Acellular Pertussis, Polio and Haemophilus Influenza Type B infection. 0.5ml by IM. Dosing is according to Immunisation Schedule under NIP.
517 Diphtheria, Tetanus, Pertussis (Acellular, component), Hepatitis B (rDNA), Poliomyelitis (Inactivated) and Haemophilus Influenzae Type B Conjugate Vaccine (adsorbed) (DTaP- IPV-HB-Hib) Injection J07CA09-963-P30-02-001 C+ For primary and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). Not applicable Dosing is according to Immunisation Schedule under NIP:
Primary: Dose of 0.5ml to be given by IM at 2, 3 & 5 months of age.
Booster: Dose of 0.5ml to be given by IM at 18 months of age.
518 Dithranol 0.1 - 5% in Vaseline/ Ointment D05AC01000G5001XX A Short contact treatment for plaque psoriasis and alopecia areata For application to skin or scalp. 0.1-0.5% suitable for overnight treatment. 1-2% for max 1 hour.
519 Dithranol 1 % in Lassars Paste D05AC01000G6001XX A Treatment of quiescent or chronic psoriasis of the skin, scalp and alopecia areata Apply liberally and carefully to the lesions with a suitable applicator. A dressing may be applied
520 Dobutamine 12.5mg/ml Injection C01CA07-110-P30-01-XX A Hypotension and heart failure None Initial 0.5-1 mcg/kg/min by IV, maintenance 2.5-10mcg/kg/min. Frequently,doses up to 20mcg/kg/min are required for adequate hemodynamic improvement. On rare occasions,infusion rates up to 40mcg/kg/min
521 Docetaxel 20mg/ml Injection L01CD02-000-P30-03-XXX A* i) Breast Cancer
ii) Non-small cell lung cancer
iii) Prostate cancer
iv) Gastric adenocarcinoma
v) Head and neck cancer
vi) Ovarian cancer		 Two dosing regimens:
a. 50 mg/m2 every 2 weeks, intravenous
b. 75 to 100 mg/m2 every 3 weeks, intravenous.

Dosing is according to product insert/protocol.
522 Docetaxel 40mg/ml Injection L01CD0-000-P30-02-XXX A* i) Breast Cancer
ii) Non-small cell lung cancer
iii) Prostate cancer
iv) Gastric adenocarcinoma
v) Head and neck cancer
vi)Ovarian cancer		 Two dosing regimens:
a. 50 mg/m2 every 2 weeks, intravenous
b. 75 to 100 mg/m2 every 3 weeks, intravenous.

Dosing is according to product insert/protocol.
523 Dolutegravir 50mg Tablet J05AX12-000-T32-01-XXX A/KK Dolutegravir is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age. For patients who are :
- not able to tolerate; or
- failing treatment or resistant to first line therapy (efavirenz and nevirapine).		 i) HIV-1 patients without documented or clinically suspected resistance to the integrase class: 50 mg (one tablet), once daily, orally.
ii) HIV-1 patients with resistance to the integrase class: 50 mg (one tablet), twice daily, orally.
524 Dolutegravir 50mg, Lamivudine 300mg, Tenofovir Disoproxil Fumarate 300mg Film-Coated Tablets J05AR27-964-T32-01-XXX A/KK Indicated for use alone as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing 40 kg or greater. None One tablet once daily
525 Domperidone 1 mg/ml Suspension A03FA03000L8001XX B Nausea, vomiting, dyspepsia, gastro-esophageal reflux Adults and adolescents ≥ 12 years of age and weighing ≥ 35kg & children < 12 years of age and weighing ≥ 35kg: 10ml three to four times per day. Maximum dose: 40mg/day.
Adults and adolescents (≥ 12 years of age) weighing < 35kg: 0.25mg/kg three to four times per day. Maximum dose: 35mg/day.
526 Domperidone 10 mg Tablet A03FA03253T1001XX B Nausea, vomiting, dyspepsia, gastro-esophageal reflux Adults and adolescents ≥ 12 years of age and weighing ≥ 35kg & children < 12 years of age and weighing ≥ 35kg: 10mg three to four times per day. Maximum dose: 40mg/day
527 Donepezil HCl 10 mg Tablet N06DA02-110-T10-02-XXX A/KK Treatment of mild, moderate and severe dementia in Alzheimer's disease Psychiatrists, Neurologists, Geriatricians, Family Medicine Specialists trained in Mental Health Disorders 5 - 10 mg once daily at bedtime. Maximum 10 mg daily
528 Donepezil HCl 10mg Orodispersible Tablet N06DA02-110-T40-02-XXX A* Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease Psychiatrists, neurologists and geriatricians only Initiated at 5mg/day (one a day dosing), should be maintained for at least 1 month in order to allow the earliest clinical responses and to allow steady state concentration to be achieved. The maximum recommended daily dose is 10 mg.
529 Donepezil HCl 5 mg Tablet N06DA02-110-T10-01-XXX A/KK Treatment of mild, moderate and severe dementia in Alzheimer's disease. Psychiatrists, Neurologists, Geriatricians, Family Medicine Specialists trained in Mental Health Disorders 5 - 10 mg once daily at bedtime. Maximum 10 mg daily
530 Donepezil HCl 5mg Orodispersible Tablet N06DA02-110-T40-01-XXX A* Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease Psychiatrists, neurologists and geriatricians only Initiated at 5mg/day (one a day dosing), should be maintained for at least 1 month in order to allow the earliest clinical responses and to allow steady state concentration to be achieved. The maximum recommended daily dose is 10 mg.
531 Dopamine HCl 40 mg/ml Injection C01CA04110P3001XX B Non-hypovolemic hypotension None Initial dose 2-5  mcg/kg/min with incremental changes of 5-10 mcg/kg/min at 10-15 minutes intervals until adequate response is noted. Most patients are maintained at less than 20 mcg/kg/min. If dosage exceeds 50 mcg/kg/min, assess renal function frequently
532 Dorzolamide HCl 2% Ophthalmic Solution S01EC03-110-D20-01-XXX A* All glaucoma patients where beta-blockers are contraindicated and when intraocular pressure is not well controlled by other drugs None Monotherapy : 1 drop 3 times daily. Adjunctive therapy with an ophthalmic beta-blocker : 1 drop 2 times daily. When substituting for another ophthalmic antiglaucoma agent with this product, discontinue the other agent after proper dosing on one day and start Trusopt on the next day. If more than 1 topical ophthalmic drug is used, the drugs should be administered at least 10 mins apart
533 Dothiepin HCl 25 mg Capsule N06AA16110C1001XX A Depression of any aetiology Initially 75 mg (ELDERLY 50-75 mg) daily in divided doses or single dose at bedtime, increased gradually as necessary to 150 mg daily (ELDERLY 75 mg may be sufficient), up to 225 mg daily in some circumstances. CHILD is not recommended
534 Dothiepin HCl 75 mg Tablet N06AA16110T1001XX A Depression of any aetiology Initially 75 mg (ELDERLY 50-75 mg) daily in divided doses or single dose at bedtime, increased gradually as necessary to 150 mg daily (ELDERLY 75 mg may be sufficient), up to 225 mg daily in some circumstances. CHILD is not recommended
535 Doxazosin Mesilate 4mg CR Tablet C02CA04196T5001XX A* Benign Prostatic Hyperplasia None 4 mg once daily to maximum 8mg/day
536 Doxorubicin HCl 2mg/mL Injection L01DB01110P4002XX A i) Solid tumours, leukaemia, non-Hodgkin's lymphoma
ii) Leukaemia (ALL induction)
iii) Multiple myeloma		 i) 30 - 75 mg/m2 IV as a single dose at 21 day intervals
ii) 25 - 45 mg/m2 once a week for the first 4 weeks during induction or re-induction phase (refer to specific protocol. Caution: Total cumulative dose of doxorubicin must not exceed 550 mg/m2 due to risk of cardiotoxicity. CHILD: 30 mg/m2/dose over 6 - 24 hours for 1 - 2 days. Need to check cardiac function closely by echocardiography every cumulative dose of 100 mg/m2 to maximum 360 mg/m2
iii) 9 mg/m2 over 24 hours infusion for 4 days at monthly intervals
537 Doxycycline 100mg Capsule J01AA02-000-C10-01-XXX B Prophylaxis and treatment for infections due to susceptible organisms. None Prophylaxis
100-200mg daily or weekly

Treatment
100-300mg daily

Dosing is individualised based on type of infections and according to product insert/protocol
538 Doxycycline 100mg Tablet J01AA02-000-T10-01-XXX B Prophylaxis and treatment for infections due to susceptible organisms None Prophylaxis
100-200mg daily or weekly

Treatment
100-300mg daily

Dosing is individualised based on type of infections and according to product insert/protocol
539 Dulaglutide 0.75mg Solution for Injection in Pre-Filled Pen A10BJ05-000-P50-01-xxx A* Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
• in addition to other glucose lowering medicinal products for the treatment of diabetes.		 i. HbA1c > 8.0% while on ≥2 Oral Glucose Lowering Drugs (OGLDs) and basal insulin AND
ii. BMI > 30 kg/m2 AND
iii. Very High CV Risk based on European Society of Cardiology (ESC) 2023 Risk Category:
a. Clinically established ASCVD or
b. Severe TOD (eGFR <45 mL/min/1.73m2 irrespective of albuminuria; or eGFR 45–59 mL/min/1.73m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease in at least three different sites or
c. 10-year CVD risk ≥20% using SCORE2-Diabetes
iv. To be prescribed by Endocrinologists only
Monotherapy: The recommended dose is 0.75 mg once weekly.
Add-on therapy: The recommended dose is 1.5 mg once weekly. For potentially vulnerable populations 0.75 mg once weekly can be considered as a starting dose.
540 Dulaglutide 1.5mg Solution for Injection in Pre-Filled Pen A10BJ05-000-P50-02-xxx A* Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
• in addition to other glucose lowering medicinal products for the treatment of diabetes.		 i. HbA1c > 8.0% while on ≥2 Oral Glucose Lowering Drugs (OGLDs) and basal insulin AND
ii. BMI > 30 kg/m2 AND
iii. Very High CV Risk based on European Society of Cardiology (ESC) 2023 Risk Category:
a. Clinically established ASCVD or
b. Severe TOD (eGFR <45 mL/min/1.73m2 irrespective of albuminuria; or eGFR 45–59 mL/min/1.73m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease in at least three different sites or
c. 10-year CVD risk ≥20% using SCORE2-Diabetes
iv. To be prescribed by Endocrinologists only		 Monotherapy: The recommended dose is 0.75 mg once weekly.
Add-on therapy: The recommended dose is 1.5 mg once weekly. For potentially vulnerable populations 0.75 mg once weekly can be considered as a starting dose.

Pages